Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that the Company has recently won several new contracts to support pharmaceutical clients in delivering virtual clinical trials, including two contracts collectively worth over £1 million - the majority of which is expected to be recognised this financial year.
28 May, 2020
CHOSOURCE platform to be combined with Rentschler Biopharma’s novel in-house cell line development process to provide speed, stability and high yield
22 May, 2020
Glasgow, Scotland, 21 May 2020 - Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to remove disease causing proteins selectively and efficiently, today announced the appointment of Dr Ian Churcher as Chief Scientific Officer (CSO).
21 May, 2020
A ‘virtual VMIC’ will be created to rapidly expand the UK capacity to manufacture a COVID-19 vaccine. VMIC’s permanent facility, currently being built, will be fast tracked to come online in Summer 2021 – a year ahead of schedule. Manufacturing output at the permanent facility will be scaled-up 20fold to ensure enough doses of a pandemic vaccine for the UK population within 4-6 months of opening.
18 May, 2020